Engin Çeşmeci

ORCID: 0000-0002-2158-9075
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Heart Failure Treatment and Management
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Immune Cell Function and Interaction
  • Iron Metabolism and Disorders
  • Hemoglobinopathies and Related Disorders
  • Global Cancer Incidence and Screening
  • COVID-19 and healthcare impacts
  • Esophageal and GI Pathology
  • Erythropoietin and Anemia Treatment
  • Child Nutrition and Feeding Issues
  • Pharmaceutical Practices and Patient Outcomes
  • Ear and Head Tumors
  • Dysphagia Assessment and Management
  • Economic and Financial Impacts of Cancer
  • Viral-associated cancers and disorders

Hacettepe University
2020-2023

Background We compared the new outpatient clinic referrals during first 10 months of COVID-19 pandemic with year before. Methods baseline characteristics 2208 in 2020 (n=922) and 2019 (n=1286) Χ 2 Mann-Whitney U tests calculated ORs binary logistic regression. To evaluate expected changes cancer survival secondary to stage migration, we used 5-year data Survival, Epidemiology End Results (SEER) Program 2010–2016. The percentage patients inoperable or metastatic disease was significantly...

10.1136/bmjspcare-2021-003301 article EN other-oa BMJ Supportive & Palliative Care 2021-10-28

Introduction Kaposi sarcoma (KS) is an angioproliferative malignancy associated with HHV-8. It mostly observed in patients affected by HIV and/or chronic immunosuppression, while classic KS without underlying immunosuppression are relatively rare. Systemic chemotherapy used for advanced diseases, although there no consensus treatment algorithms. With the demonstration of PD-1 expression KS, immune-checkpoint-inhibitors (ICI) emerged as possible options. Notwithstanding, data ICIs limited to...

10.1177/1078155220985589 article EN Journal of Oncology Pharmacy Practice 2021-01-11

Anemia remains an essential concern affecting the quality of life and survival cancer patients. Although there are different approaches to treating anemia in patients, number studies reporting efficacy iron replacement patients is limited. In this study, safety carboxymaltose, a parenteral treatment option, anemia, were examined retrospectively. A total 1102 adult who received IV ferric carboxymaltose at Hacettepe Oncology Hospital between 2014 2020 included. The mean hemoglobin change...

10.3390/curroncol30110703 article EN cc-by Current Oncology 2023-11-02
Coming Soon ...